ClinicalTrials.gg
Active, not recruitingNCT03470922RELATIVITY-047Updated Sep 9, 2025Results posted

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

A Phase 2/3 interventional study of Relatlimab and Nivolumab in Melanoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 127 sites in 25 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
714
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.

Enrollment
12th of 75
714 · median 107
Started
2018
with 4 others
Phase 2/3
2 of 111
none open now
Registered
85th of 111
by date

Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2018, is one of 2 in phase 2/3, and was the 85th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Melanoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.

03

Conditions studied

  • Melanoma

Keywords

  • Cancer
  • Advanced Cancer
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Participants must have confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system
  • Participants must not have had prior systemic anticancer therapy for unresectable or melanoma
  • Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses

Exclusion criteria

Exclusion Criteria:

  • Participants must not have active or
  • Participants must not have uveal melanoma
  • Participants must not have an active, known, or suspected disease

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
714 participants (actual)

Study arms

  • Experimental
    Arm A: Relatlimab + Nivolumab

    Combination

    Biological: Relatlimab · Biological: Nivolumab

  • Experimental
    Arm B: Nivolumab

    Monotherapy

    Biological: Nivolumab

Interventions

  • BiologicalRelatlimab

    Specified dose on specified day

  • BiologicalNivolumab

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death.

    Time frame: From randomization to date of first documented tumor progression or death (up to approximately 33 months)

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For subjects that are alive, their survival time will be censored at the date of last contact ("last known alive date").

    Time frame: From randomization to the date of death (up to approximately 3 years)

  2. Overall Response Rate (ORR)

    Objective response rate (ORR) is defined as the number of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) based on BICR assessments (using RECIST v1.1 criteria).

    Time frame: From randomization up to approximately 3 years

Other outcomes

  1. The Number of Participants Experiencing Adverse Events (AEs)

    The number of participants experiencing adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)

  2. The Number of Participants Experiencing Serious Adverse Events (SAEs)

    The number of participants experiencing serious adverse events (SAEs). A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)

  3. The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

    The number of participants experiencing adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)

  4. The Number of Participant Deaths in the Study

    The number of participant deaths in the study.

    Time frame: From first dose up to approximately 33 months

  5. The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests

    The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)

  6. The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests

    The number of participants with clinical laboratory test abnormalities in specific thyroid tests based on US conventional units.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)

07

Results

Posted Mar 29, 2022

Participant flow

Participant flow — Overall Study
MilestoneArm A: Relatlimab + NivolumabArm B: Nivolumab
Started355359
Completed237227
Not completed118132
Withdrew: Death107118
Withdrew: Lost to follow-up55
Withdrew: Participant withdrew consent49
Withdrew: Other reasons10
Withdrew: Not reported10

Outcome measures

PrimaryProgression Free Survival (PFS)

Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death.

Time frame:
From randomization to date of first documented tumor progression or death (up to approximately 33 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsArm A: Relatlimab + NivolumabArm B: Nivolumab
Progression Free Survival (PFS)10.12 (6.37 to 15.74)4.63 (3.38 to 5.62)
Statistical analysis
  • Arm A: Relatlimab + Nivolumab vs Arm B: Nivolumab · Log Rank · p = 0.0055 · Cox proportional hazard: 0.75 · 95% CI 0.62 to 0.92Log-rank test stratified by LAG-3 (≥ 1% vs \< 1%), BRAF (mutation positive vs mutation wild-type), AJCC M-stage (M0/M1any\[0\] vs M1any\[1\])
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For subjects that are alive, their survival time will be censored at the date of last contact ("last known alive date").

Time frame:
From randomization to the date of death (up to approximately 3 years)

Results for this outcome have not been posted.

SecondaryOverall Response Rate (ORR)

Objective response rate (ORR) is defined as the number of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) based on BICR assessments (using RECIST v1.1 criteria).

Time frame:
From randomization up to approximately 3 years

Results for this outcome have not been posted.

Other pre-specifiedThe Number of Participants Experiencing Adverse Events (AEs)

The number of participants experiencing adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs)
ParticipantsArm A: Relatlimab + NivolumabArm B: Nivolumab
The Number of Participants Experiencing Adverse Events (AEs)345339
Other pre-specifiedThe Number of Participants Experiencing Serious Adverse Events (SAEs)

The number of participants experiencing serious adverse events (SAEs). A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsArm A: Relatlimab + NivolumabArm B: Nivolumab
The Number of Participants Experiencing Serious Adverse Events (SAEs)121105
Other pre-specifiedThe Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

The number of participants experiencing adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
ParticipantsArm A: Relatlimab + NivolumabArm B: Nivolumab
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation6941
Other pre-specifiedThe Number of Participant Deaths in the Study

The number of participant deaths in the study.

Time frame:
From first dose up to approximately 33 months
Reported as:
Count of participants · Participants
The Number of Participant Deaths in the Study
ParticipantsArm A: Relatlimab + NivolumabArm B: Nivolumab
The Number of Participant Deaths in the Study108119
Other pre-specifiedThe Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests

The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
ParticipantsArm A: Relatlimab + NivolumabArm B: Nivolumab
ALT OR AST > 3XULN2615
ALT OR AST> 5XULN117
ALT OR AST> 10XULN44
ALT OR AST > 20XULN02
TOTAL BILIRUBIN > 2XULN25
ALP > 1.5xULN3430
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 1 DAY22
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 30 DAYS22
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY21
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS21
Other pre-specifiedThe Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests

The number of participants with clinical laboratory test abnormalities in specific thyroid tests based on US conventional units.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests
ParticipantsArm A: Relatlimab + NivolumabArm B: Nivolumab
TSH > ULN106106
TSH > ULN WITH TSH <= ULN AT BASELINE8482
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN6348
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN77
TSH > ULN WITH FT3/FT4 TEST MISSING89
TSH < LLN8984
TSH <LLN WITH TSH >= LLN AT BASELINE7978
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN5140
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN63
TSH < LLN WITH FT3/FT4 TEST MISSING117

Adverse events

Collected over From first dose to up to 100 days post last dose (up to approximately 33 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Relatlimab + Nivolumab108/355 (30.4%)155/355 (43.7%)314/355 (88.5%)
Arm B: Nivolumab119/359 (33.1%)140/359 (39%)298/359 (83%)
Most frequent serious events
Showing 10 of 242
Most frequent serious events
EventArm A: Relatlimab + NivolumabArm B: Nivolumab
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)39/35547/359
General physical health deteriorationGeneral disorders2/3556/359
Urinary tract infectionInfections and infestations3/3556/359
AnaemiaBlood and lymphatic system disorders5/3554/359
Adrenal insufficiencyEndocrine disorders5/3550/359
ColitisGastrointestinal disorders5/3551/359
PneumoniaInfections and infestations5/3553/359
PyrexiaGeneral disorders3/3555/359
Acute myocardial infarctionCardiac disorders4/3552/359
MyocarditisCardiac disorders4/3551/359
Most frequent other events
Showing 10 of 36
Most frequent other events
EventArm A: Relatlimab + NivolumabArm B: Nivolumab
FatigueGeneral disorders104/35574/359
PruritusSkin and subcutaneous tissue disorders88/35562/359
ArthralgiaMusculoskeletal and connective tissue disorders84/35554/359
DiarrhoeaGastrointestinal disorders82/35562/359
HeadacheNervous system disorders64/35547/359
NauseaGastrointestinal disorders63/35559/359
RashSkin and subcutaneous tissue disorders62/35549/359
HypothyroidismEndocrine disorders58/35547/359
Decreased appetiteMetabolism and nutrition disorders55/35527/359
AnaemiaBlood and lymphatic system disorders50/35537/359

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: Relatlimab + NivolumabArm B: NivolumabTotal
Mean61.2 ± 14.161.2 ± 14.061.2 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Relatlimab + NivolumabArm B: NivolumabTotal
Female145153298
Male210206416
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Relatlimab + NivolumabArm B: NivolumabTotal
Hispanic or Latino272047
Not Hispanic or Latino144147291
Unknown or Not Reported184192376
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Relatlimab + NivolumabArm B: NivolumabTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American055
White342348690
More than one race000
Unknown or Not Reported13518
08

Study locations

127 sites
  • Local Institution - 0010
    Tucson, Arizona 85724-5024, United States
  • Local Institution - 0020
    Los Angeles, California 90095, United States
  • Coastal Integrative Cancer Care
    San Luis Obispo, California 93401, United States
  • Local Institution - 0116
    Santa Barbara, California 93105, United States
  • Local Institution - 0012
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0013
    Jacksonville, Florida 32224, United States
  • Local Institution - 0117
    Orlando, Florida 32806, United States
  • Local Institution - 0007
    Tampa, Florida 33612, United States
  • Local Institution - 0038
    Atlanta, Georgia 30342, United States
  • Local Institution - 0016
    Chicago, Illinois 60611, United States
  • Local Institution - 0114
    Fort Wayne, Indiana 46804, United States
  • Local Institution - 0077
    Baltimore, Maryland 21237, United States
  • Local Institution - 0120
    Baltimore, Maryland 21287, United States
  • Local Institution - 0014
    Boston, Massachusetts 02215, United States
  • Local Institution - 0134
    Boston, Massachusetts 02215, United States
  • Local Institution - 0015
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0009
    Minneapolis, Minnesota 55407, United States
  • Local Institution - 0011
    Rochester, Minnesota 55905, United States
  • Local Institution - 0018
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0019
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0076
    Dallas, Texas 75246, United States
  • Local Institution - 0008
    Houston, Texas 77030, United States
  • Local Institution - 0135
    Buenos Aires, Distrito Federal 1121, Argentina
  • Local Institution - 0002
    Capital Federal, Distrito Federal C1280AEB, Argentina
  • Local Institution - 0004
    Buenos Aires, 1199, Argentina
  • Local Institution - 0003
    Buenos Aires, 1426, Argentina
  • Local Institution - 0005
    Buenos Aires, 4102-4200, Argentina
  • Local Institution - 0042
    North Sydney, New South Wales 2060, Australia
  • Local Institution - 0043
    Waratah, New South Wales 2298, Australia
  • Local Institution - 0041
    Greenslopes, Queensland 4120, Australia
  • Local Institution - 0045
    Southport, Queensland 4215, Australia
  • Local Institution - 0133
    Bedford Park, South Australia 5042, Australia
  • Local Institution - 0044
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0036
    Graz, Styria 8036, Austria
  • Local Institution - 0037
    Salzburg, 5020, Austria
  • Local Institution - 0035
    Vienna, 1090, Austria
  • Local Institution - 0047
    Brussels, 1090, Belgium
  • Local Institution - 0049
    Brussels, 1200, Belgium
  • Local Institution - 0048
    Ghent, 9000, Belgium
  • Local Institution - 0058
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0057
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Local Institution - 0061
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution - 0073
    Santa Cruz do Sul, Rio Grande do Sul 96810-110, Brazil
  • Local Institution - 0063
    São Paulo, São Paulo 05651-901, Brazil
  • Local Institution - 0059
    Rio de Janiro, 20220-410, Brazil
  • Local Institution - 0060
    São Paulo, 01246-000, Brazil
  • Local Institution - 0062
    São Paulo, 01509-010, Brazil
  • Local Institution - 0124
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution - 0068
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution - 0128
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0123
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0075
    Montreal, Quebec H4A 3J1, Canada
  • Local Institution - 0001
    Santiago, Santiago Metropolitan, Chile
  • Local Institution - 0096
    Medellín, Antioquia 050030, Colombia
  • Local Institution - 0095
    Bogotá, 110321, Colombia
  • Local Institution - 0105
    Aarhus N, Central Jutland 8200, Denmark
  • Local Institution - 0103
    Herlev, 2730, Denmark
  • Local Institution - 0104
    Odense, 5000, Denmark
  • Local Institution - 0100
    Helsinki, Uusimaa 00290, Finland
  • Local Institution - 0102
    Oulu, 90220, Finland
  • Local Institution - 0119
    Tampere, 33521, Finland
  • Local Institution - 0101
    Turku, 20520, Finland
  • Local Institution - 0084
    Rennes, Ille-et-Vilaine 35042, France
  • Local Institution - 0079
    Amiens, Somme 80000, France
  • Local Institution - 0080
    Bordeaux, 33075, France
  • Local Institution - 0085
    Lille, 59000, France
  • Local Institution - 0081
    Marseille, 13011, France
  • Local Institution - 0083
    Paris, 75010, France
  • Local Institution - 0078
    Pierre-Bénite, 69310, France
  • Local Institution - 0082
    Poitiers, 86000, France
  • Local Institution - 0132
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Local Institution - 0131
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Local Institution - 0071
    Quedlinburg, Saxony-Anhalt 06484, Germany
  • Local Institution - 0032
    Buxtehude, 21614, Germany
  • Local Institution - 0029
    Cologne, 50937, Germany
  • Local Institution - 0030
    Erfurt, 99089, Germany
  • Local Institution - 0027
    Essen, 45147, Germany
  • Local Institution - 0033
    Hanover, 30625, Germany
  • Local Institution - 0074
    Homburg / Saar, 66421, Germany
  • Local Institution - 0028
    Lübeck, 23538, Germany
  • Local Institution - 0072
    Mannheim, 68167, Germany
  • Local Institution - 0034
    München, 81675, Germany
  • Local Institution - 0031
    Würzburg, 97080, Germany
  • Local Institution - 0064
    Athens, 11526, Greece
  • Local Institution - 0065
    Thessaloniki, 54622, Greece
  • Local Institution - 0086
    Haifa, 3109601, Israel
  • Local Institution - 0088
    Jerusalem, 91120, Israel
  • Local Institution - 0087
    Ramat Gan, 52621, Israel
  • Local Institution - 0111
    Turin, Piedmont 10126, Italy
  • Local Institution - 0109
    Bergamo, 24127, Italy
  • Local Institution - 0108
    Milan, 20133, Italy
  • Local Institution - 0106
    Naples, 80131, Italy
  • Local Institution - 0110
    Padova, 35128, Italy
  • Local Institution - 0107
    Siena, 53100, Italy
  • Local Institution - 0094
    Zapopan, Jalisco 45070, Mexico
  • Local Institution - 0091
    Monterrey, Nuevo León 64060, Mexico
  • Local Institution - 0093
    Cancún, Quintana Roo 77500, Mexico
  • Local Institution - 0092
    Mérida, Yucatán 97130, Mexico
  • Local Institution - 0129
    Veracruz, 91900, Mexico
  • Local Institution - 0090
    Dunedin, 9012, New Zealand

Showing the first 100 of 127 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bautista J, Echeverria CE, Maldonado-Noboa I, Adatty-Molina J, Suarez Urresta S, Coral-Riofrio EC, Araujo-Abad S, Kyriakidis NC, Lopez-Cortes A. Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy. J Immunol Res. 2026;2026(1):e7864229. doi: 10.1155/jimr/7864229. PubMed 41811823 ↗
  • Regan MM, Ascierto PA MD, Lipson EJ, Palaia J, Moshyk A, Selvan A, Lao CD, Atkins MB MD, McDermott DF, Potluri R, Ranjan S, Bilthare S, Long GV, Stephen Hodi F, Tawbi H, Schadendorf D. Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. J Immunother Cancer. 2025 Sep 12;13(9):e012747. doi: 10.1136/jitc-2025-012747. PubMed 40940136 ↗
  • Lipson EJ, Stephen Hodi F, Tawbi H, Schadendorf D, Ascierto PA, Matamala L, Gutierrez EC, Rutkowski P, Gogas HJ, Lao CD, Menezes JJ, Dalle S, Arance A, Gaudy-Marqueste C, Chen B, Jackson W, Mukherjee S, Dolfi S, Long GV. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer. 2025 Jul 25;225:115547. doi: 10.1016/j.ejca.2025.115547. Epub 2025 Jun 3. PubMed 40513285 ↗
  • Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol. 2025 May;43(13):1546-1552. doi: 10.1200/JCO.24.01124. Epub 2024 Dec 13. PubMed 39671533 ↗
  • Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Salman P, Castillo Gutierrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski De Menezes J, Dalle S, Arance A, Grob JJ, Keidel S, Shaikh A, Sobiesk AM, Dolfi S, Tawbi HA. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid. 2023 Apr;2(4):EVIDoa2200239. doi: 10.1056/EVIDoa2200239. Epub 2023 Mar 22. PubMed 38320023 ↗
  • Schadendorf D, Tawbi H, Lipson EJ, Stephen Hodi F, Rutkowski P, Gogas H, Lao CD, Grob JJ, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. Eur J Cancer. 2023 Jul;187:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22. PubMed 37167764 ↗
  • Raschi E, Comito F, Massari F, Gelsomino F. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy. 2023 Feb;15(2):85-91. doi: 10.2217/imt-2022-0172. Epub 2023 Jan 11. PubMed 36628573 ↗
  • Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. PubMed 34986285 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jan 2021, 33 months.

Results were first posted in Mar 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2018
First posted
Mar 20, 2018
StartActual
Apr 11, 2018
Primary completionActual
Jan 25, 2021
CompletionEst.
Dec 15, 2030
Results first posted
Mar 29, 2022
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03470922
Responsible party
Sponsor
First posted
Mar 20, 2018
Start date
Apr 11, 2018
Primary completion
Jan 25, 2021
Completion
Dec 15, 2030 (estimated)
Results posted
Mar 29, 2022
Last update
Sep 9, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion